Allogene Therapeutics earnings were -$281.9M for the trailing 12 months ending Jun 30, 2024, with N/A growth year over year. The latest ALLO earnings report on Jun 30, 2024 announced Q2 2024 earnings of -$66.4M, up 2.1% from last quarter. For the last reported fiscal year 2023 ending Dec 31, 2023, ALLO reported annual earnings of -$327.3M, with -3.9% growth. The next ALLO earnings date is Oct 31, 2024.
Allogene Therapeutics Earnings Reports & History FAQ
What were Allogene Therapeutics's earnings last quarter?
On ALLO's earnings call on Invalid Date, Allogene Therapeutics (NASDAQ: ALLO) reported Q2 2024 earnings per share (EPS) of -$0.35, up 35.19% year over year. Total ALLO earnings for the quarter were -$66.36 million. In the same quarter last year, Allogene Therapeutics's earnings per share (EPS) was -$0.54.
The next ALLO earnings date is Invalid Date. Add ALLO to your watchlist to be reminded of Allogene Therapeutics's next earnings date.
What was ALLO's earnings growth in the past year?
As of Allogene Therapeutics's earnings date in Invalid Date, Allogene Therapeutics's earnings has grown year over year. ALLO earnings in the past year totalled -$281.93 million.
Is Allogene Therapeutics profitable or losing money?
As of the last Allogene Therapeutics earnings report, Allogene Therapeutics is currently losing money. Allogene Therapeutics's net profit (also called net income) for the twelve months ending Jun 30, 2024 was -$281.93 million, a 22.75% decrease year over year.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.